Moreover, PDAC patients who were prescribed angiotensin converting enzyme inhibitors or angiotensin receptor blockers to treat their hypertension were associated with better clinical outcomes compared to gemcitabine monotherapy (Nakai et al., 2010). This evidence concerns the gene ACE and Hypertension.